bioAffinity Technologies, Inc.
BIAF
$0.4698
-$0.0292-5.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.36M | 9.37M | 7.32M | 4.94M | 2.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.36M | 9.37M | 7.32M | 4.94M | 2.53M |
| Cost of Revenue | 5.98M | 6.09M | 4.72M | 3.31M | 1.74M |
| Gross Profit | 3.38M | 3.28M | 2.60M | 1.62M | 791.60K |
| SG&A Expenses | 9.94M | 9.24M | 8.90M | 7.83M | 6.79M |
| Depreciation & Amortization | 605.60K | 600.80K | 507.10K | 377.60K | 249.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.32M | 17.72M | 15.99M | 13.30M | 10.51M |
| Operating Income | -8.95M | -8.35M | -8.67M | -8.36M | -7.97M |
| Income Before Tax | -9.03M | -8.43M | -8.72M | -8.35M | -7.92M |
| Income Tax Expenses | 11.70K | 14.00K | 13.70K | 12.90K | 21.00K |
| Earnings from Continuing Operations | -9.04 | -8.45 | -8.74 | -8.37 | -7.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.04M | -8.45M | -8.74M | -8.37M | -7.94M |
| EBIT | -8.95M | -8.35M | -8.67M | -8.36M | -7.97M |
| EBITDA | -8.35M | -7.75M | -8.16M | -7.98M | -7.72M |
| EPS Basic | -0.75 | -0.80 | -0.90 | -0.92 | -0.90 |
| Normalized Basic EPS | -0.47 | -0.50 | -0.56 | -0.57 | -0.56 |
| EPS Diluted | -0.75 | -0.80 | -0.90 | -0.92 | -0.90 |
| Normalized Diluted EPS | -0.47 | -0.50 | -0.56 | -0.57 | -0.56 |
| Average Basic Shares Outstanding | 48.48M | 43.03M | 39.34M | 36.47M | 34.99M |
| Average Diluted Shares Outstanding | 48.48M | 43.03M | 39.34M | 36.47M | 34.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |